On May 28, 2015, the Federal Trade Commission announced the settlement of its 2008 lawsuit against Cephalon, Inc. , which alleged that Cephalon had made "reverse payments" to four generic drug manufacturers in order to delay sales of generic versions of its branded sleep disorder drug Provigil. According to the FTC, Cephalon had agree to pay the four generic companies a total of more than $300 million, purportedly for the purchase of an active pharmaceutical ingredient, the licensing of intellectual property, and the co-development rights in a new drug.